The FDA Have Awarded Orphan Drug Designation to an Experimental Treatment for Dermatomyositis
Aymanjed / Pixabay

The FDA Have Awarded Orphan Drug Designation to an Experimental Treatment for Dermatomyositis

The US Food and Drug Administration has awarded Orphan Drug Designation to the drug lenabasum as a treatment for dermatomyositis. The use of lenabasum for treating this condition, and others,…

Continue Reading The FDA Have Awarded Orphan Drug Designation to an Experimental Treatment for Dermatomyositis

Experimental Treatment for Dermatomyositis Fails to Meet Endpoints in Phase 2 Trial

According to a story from globenewswire.com, the biopharmaceutical company Idera Pharmaceuticals recently released the data from its Phase 2 trial for IMO-8400, an investigational product in development for the treatment…

Continue Reading Experimental Treatment for Dermatomyositis Fails to Meet Endpoints in Phase 2 Trial
For Ten Years this Woman Has Avoided Sunlight Because of Dermatomyositis
https://pixabay.com/en/sunset-birds-cloud-sun-sky-red-1625073/

For Ten Years this Woman Has Avoided Sunlight Because of Dermatomyositis

According to Port City Daily, 21-year-old Haley Swanson has been living with dermatomyositis for 10 years. She was diagnosed at age 11 with the autoimmune condition, which means that her…

Continue Reading For Ten Years this Woman Has Avoided Sunlight Because of Dermatomyositis